Content by National Cancer Centre Singapore

|2 min read

Liver Cancer Adjuvant Immunotherapy Improved Survival in Phase 3 Trial

Some 70–90 percent of patients with hepatocellular carcinoma experience cancer recurrence after curative treatment
Page 1 of 1